Pioglitazone and rosiglitazone decrease prostaglandin E2 in non-small-cell lung cancer cells by up-regulating 15-hydroxyprostaglandin dehydrogenase

Molecular Pharmacology

Volumn 71, Issue 6, 2007, Pages 1715-1720

  Hazra, Saswati ^a   Batra, Raj K ^a,b   Tai, Hsin H ^c   Sharma, Sherven ^a,b   Cui, Xiaoyan ^a   Dubinett, Steven M ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

^c University of Kentucky   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

15 HYDROXYPROSTAGLANDIN DEHYDROGENASE; 2 CHLORO 5 NITROBENZANILIDE; CYCLOOXYGENASE 2; MICROSOME ENZYME; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; PROSTAGLANDIN E SYNTHASE; PROSTAGLANDIN E SYNTHASE 1; PROSTAGLANDIN E SYNTHASE 2; PROSTAGLANDIN E2; ROSIGLITAZONE; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL; CANCER GROWTH; CATABOLISM; CONTROLLED STUDY; CYTOSOL; DEGRADATION KINETICS; DOWN REGULATION; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME REGULATION; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS INHIBITION; RECEPTOR UPREGULATION; STATISTICAL ANALYSIS; UPREGULATION;

CARCINOMA, NON-SMALL-CELL LUNG; CELLS, CULTURED; CYCLOOXYGENASE 2; DINOPROSTONE; HUMANS; HYDROXYPROSTAGLANDIN DEHYDROGENASES; HYPOGLYCEMIC AGENTS; MEMBRANE PROTEINS; PPAR GAMMA; THIAZOLIDINEDIONES; UP-REGULATION;

EID: 34347353320     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.106.033357     Document Type: Article

References (38)

1. Backlund MG, Mann JR, Holla VR, Buchanan FG, Tai HH, Musiek ES, Milne GL, Katkuri S, and DuBois RN (2005) 15-Hydroxyprostaglandin dehydrogenase is down-regulated in colorectal cancer. J Biol Chem 280:3217-3223.
2. Chang TH and Szabo E (2000) Induction of differentiation and apoptosis by ligands of peroxisome proliferator-activated receptor gamma in non-small cell lung cancer. Cancer Res 60:1129-1138.
3. Chawla A, Barak Y, Nagy L, Liao D, Tontonoz P, and Evans RM (2001) PPARgamma dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation. Nat Med 7:48-52.
4. +-dependent 15-hydroxyprostaglandin dehydrogenase (15-PGDH) by cyclooxygenase inhibitors and chemopreventive agents. Prostaglandins Leukot Essent Fatty Acids 67:461-465.
5. Consoli A and Devangelio E (2005) Thiazolidinediones and inflammation. Lupus 14:794-797.
6. Dannenberg AJ and Zakim D (1999) Chemoprevention of colorectal cancer through inhibition of cyclooxygenase-2. Semin Oncol 26:499-504.
7. +-linked 15-hydroxyprostaglandin dehydrogenase (15-PGDH) behaves as a tumor suppressor in lung cancer. Carcinogenesis 26:65-72.
8. Durbin RJ (2004) Thiazolidinedione therapy in the prevention/delay of type 2 diabetes in patients with impaired glucose tolerance and insulin resistance. Diabetes Obes Metab 6:280-285.
9. Gurnell M, Wentworth JM, Agostini M, Adams M, Collingwood TN, Provenzano C, Browne PO, Rajanayagam O, Burris TP, Schwabe JW, et al. (2000) A dominant-negative peroxisome proliferator-activated receptor γ (PPARγ) mutant is a constitutive repressor and inhibits PPARγ-mediated adipogenesis. J Biol Chem 275: 5754-5759.
10. Han S, Inoue H, Flowers LC, and Sidell N (2003) Control of COX-2 gene expression through peroxisome proliferator-activated receptor γ in human cervical cancer cells. Clin Cancer Res 9:4627-4635.
11. Heuze-Vourc'h N, Zhu L, Krysan K, Batra RK, Sharma S, and Dubinett SM (2003) Abnormal interleukin 10Ralpha expression contributes to the maintenance of elevated cyclooxygenase-2 in non-small cell lung cancer cells. Cancer Res 63:766-770.
12. Huang M, Stolina M, Sharma S, Mao JT, Zhu L, Miller PW, Wollman J, Herschman H, and Dubinett SM (1998) Non-small cell lung cancer cyclooxygenase-2-dependent regulation of cytokine balance in lymphocytes and macrophages: upregulation of interleukin 10 and down-regulation of interleukin 12 production. Cancer Res 58:1208-1216.
13. Keith RL, Miller YE, Hudish TM, Girod CE, Sotto-Santiago S, Franklin WA, Nemenoff RA, March TH, Nana-Sinkam SP, and Geraci MW (2004) Pulmonary prostacyclin synthase overexpression chemoprevents tobacco smoke lung carcinogenesis in mice. Cancer Res 64:5897-5904.
14. Keshamouni VG, Arenberg DA, Reddy RC, Newstead MJ, Anthwal S, and Standiford TJ (2005) PPAR-gamma activation inhibits angiogenesis by blocking ELR+CXC chemokine production in non-small cell lung cancer. Neoplasia 7:294-301.
15. Keshamouni VG, Reddy RC, Arenberg DA, Joel B, Thannickal VJ, Kalemkerian GP, and Standiford TJ (2004) Peroxisome proliferator-activated receptor-gamma activation inhibits tumor progression in non-small-cell lung cancer. Oncogene 23:100-108.
16. Krysan K, Merchant FH, Zhu L, Dohadwala M, Luo J, Lin Y, Heuze-Vourc'h N, Põld M, Seligson D, Chia D, et al. (2004) COX-2-dependent stabilization of survivin in non-small cell lung cancer. FASEB J 18:206-208.
17. 2 and the thiazolidinedione ciglitazone through peroxisome proliferator activator receptor γ-independent mechanisms involving reactive oxygenated species. J Biol Chem 277:29681-29685.
18. Li MY, Deng H, Zhao JM, Dai D, and Tan XY (2003) PPARgamma pathway activation results in apoptosis and COX-2 inhibition in HepG2 cells. World J Gastroenterol 9:1220-1226.
19. Mao JT, Tsu IH, Dubinett SM, Adams B, Sarafian T, Baratelli F, Roth MD, and Serio KJ (2004) Modulation of pulmonary leukotriene B4 production by cyclooxygenase-2 inhibitors and lipopolysaccharide. Clin Cancer Res 10:6872-6878.
20. Molina MA, Sitja-Arnau M, Lemoine MG, Frazier ML, and Sinicrope FA (1999) Increased cyclooxygenase-2 expression in human pancreatic carcinomas and cell lines: growth inhibition by nonsteroidal anti-inflammatory drugs. Cancer Res 59:4356-4362.
21. Murakami M, and Kudo I (2006) Prostaglandin E synthase: a novel drug target for inflammation and cancer. Curr Pharm Des 12:943-954.
22. Parkin DM (2001) Global cancer statistics in the year 2000. Lancet Oncol 2:533-543.
23. Põld M, Zhu LX, Sharma S, Burdick MD, Lin Y, Lee PP, Põld A, Luo J, Krysan K, Dohadwala M, et al. (2004) Cyclooxygenase-2-dependent expression of angiogenic CXC chemokines ENA-78/CXC Ligand (CXCL) 5 and interleukin-8/CXCL8 in human non-small cell lung cancer. Cancer Res 64:1853-1860.
24. Riedl K, Krysan K, Põld M, Dalwadi H, Heuze-Vourc'h N, Dohadwala M, Liu M, Cui X, Figlin R, Mao JT, et al. (2004) Multifaceted roles of cyclooxygenase-2 in lung cancer. Drug Resist Updat 7:169-184.
25. Sandler AB and Dubinett SM (2004) COX-2 inhibition and lung cancer. Semin Oncol 31(2 Suppl 7):45-52.
26. Schmidt S, Moric E, Schmidt M, Sastre M, Feinstein DL, and Heneka MT (2004) Anti-inflammatory and antiproliferative actions of PPAR-gamma agonists on T lymphocytes derived from MS patients. J Leukoc Biol 75:478-485.
27. Schrör K, Mehta P, and Mehta JL (2005) Cardiovascular risk of selective cyclooxygenase-2 inhibitors. J Cardiovasc Pharmacol Ther 10:95-101.
28. Shamma A, Yamamoto H, Doki Y, Okami J, Kondo M, Fujiwara Y, Yano M, Inoue M, Matsuura N, Shiozaki H, et al. (2000) Up-regulation of cyclooxygenase-2 in squamous carcinogenesis of the esophagus. Clin Cancer Res 6:1229-1238.
29. Shao J, Sheng H, Inoue H, Morrow JD, and DuBois RN (2000) Regulation of constitutive cyclooxygenase-2 expression in colon carcinoma cells. J Biol Chem 275:33951-33956.
30. Smith WL, Marnett LJ, and DeWitt DL (1991) Prostaglandin and thromboxane biosynthesis. Pharmacol Ther 49:153-179.
31. Soslow RA, Dannenberg AJ, Rush D, Woerner BM, Khan KN, Masferrer J, and Koki AT (2000) COX-2 is expressed in human pulmonary, colonic, and mammary tumors. Cancer 89:2637-2645.
32. Stolina M, Sharma S, Lin Y, Dohadwala M, Gardner B, Luo J, Zhu L, Kronenberg M, Miller PW, Portanova J, et al. (2000) Specific inhibition of cyclooxygenase 2 restores antitumor reactivity by altering the balance of IL-10 and IL-12 synthesis. J Immunol 164:361-370.
33. Williams CS, Tsujii M, Reese J, Dey SK, and DuBois RN (2000) Host cyclooxygenase-2 modulates carcinoma growth. J Clin Invest 105:1589-1594.
34. Wolf I, O'Kelly J, Rubinek T, Tong M, Nguyen A, Lin BT, Tai HH, Karlan BY, and Koeffler HP (2006) 15-hydroxyprostaglandin dehydrogenase is a tumor suppressor of human breast cancer. Cancer Res 66:7818-7823.
35. Wolff H, Saukkonen K, Anttila S, Karjalainen A, Vainio H, and Ristimaki A (1998) Expression of cyclooxygenase-2 in human lung carcinoma. Cancer Res 58:4997-5001.
36. Yan M, Rerko RM, Platzer P, Dawson D, Willis J, Tong M, Lawrence E, Lutterbaugh J, Lu S, Willson JK, et al. (2004) 15-Hydroxyprostaglandin dehydrogenase, a COX-2 oncogene antagonist, is a TGF-beta-induced suppressor of human gastrointestinal cancers. Proc Natl Acad Sci U S A 101:17468-17473.
37. Yip-Schneider MT, Barnard DS, Billings SD, Cheng L, Heilman DK, Lin A, Marshall SJ, Crowell PL, Marshall MS, and Sweeney CJ (2000) Cyclooxygenase-2 expression in human pancreatic adenocarcinomas. Carcinogenesis 21:139-146.
38. Yoshizumi T, Ohta T, Ninomiya I, Terada I, Fushida S, Fujimura T, Nishimura G, Shimizu K, Yi S, and Miwa K (2004) Thiazolidinedione, a peroxisome proliferator-activated receptor-gamma ligand, inhibits growth and metastasis of HT-29 human colon cancer cells through differentiation-promoting effects. Int J Oncol 25:631-639.